Houston, TX (PRWEB) August 06, 2021 Fannin Innovation Studio announces it has been awarded a $2,000,000 Small Business Innovation Research (SBIR) Phase II
New COVID-19 vaccine candidate provides effective option for low- to mid-income countries eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
Antiviral Program for Pandemics nih.gov - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nih.gov Daily Mail and Mail on Sunday newspapers.
SNPRC at Texas Biomed awarded $37 million NIH grant to continue operations into 2026
The Southwest National Primate Research Center (SNPRC) at Texas Biomedical Research Institute (Texas Biomed) has been awarded more than $37 million from the National Institutes of Health (NIH) to continue operations into 2026. The P51 grant, given by the NIH Office of Research Infrastructure Programs, provides essential funding to house and care for nearly 2,500 non-human primates that are part of life-science research programs at Texas Biomed and partners around the globe.
Non-human primates play an essential role in pre-clinical research, including most recently helping to show that the Pfizer-BioNTech COVID-19 vaccine would be safe and effective for humans, accelerating the clinical trials. The support from NIH for our Center will ensure that we can continue this critical work in finding new treatments and vaccines against a variety of infectious diseases, while maintaining the absolute highest
Yerkes NPRC/Emory University and Institut Pasteur researchers have determined adding a combination immunotherapy to antiviral therapy (ART) is effective in generating highly functional natural killer (NK) cells that can help control and reduce simian immunodeficiency virus (SIV) in animal models. This finding is key for reducing reliance on ART and developing additional treatment options to control HIV/AIDS.